MEI Pharma presents voruciclib Phase 1b AML data at Brookline Symposium

Lite Strategy, Inc.

CMO Richard Ghalie discussed voruciclib clinical data at virtual MDS/AML symposium on May 21, 2024.
Voruciclib is an oral CDK inhibitor; ongoing Phase 1b in relapsed/refractory AML targeting resistance mechanisms.
Specific efficacy/safety results are detailed in the attached corporate presentation (Exhibit 99.1) but not excerpted in the filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.